Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...

A phase 2 trial reveals that combining intratumoral BO-112 with pembrolizumab shows potential in treating anti–PD-1-resistant ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma.

Pembrolizumab is an anti–PD-1 monoclonal antibody that has shown promising efficacy and manageable safety as monotherapy in patients with cervical cancer. 1,2 The phase III KEYNOTE-826 study evaluated ...

We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials.gov identifier: NCT02578680).Eligible patients with previously untreated metastatic nonsquamous non–small-cell lung cancer ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced cervical cancer, according to data presented at Society of Gynecologic ...